Shriram Finance Eyes 1% Funding Cost Drop Post-MUFG Infusion

Shriram Finance expects its cost of funds to decline by approximately 1% in the wake of a significant capital infusion from MUFG. This anticipated reduction is poised to enhance the company's financial efficiency and profitability. The capital proceeds will be deployed strategically across two key areas. Roughly 50% of the funds are earmarked for restructuring Shriram Finance's existing liabilities. This move is expected to optimize its balance sheet, potentially lowering overall interest expenses and improving credit metrics. By actively managing its debt portfolio, Shriram Finance aims to secure more favorable terms and conditions, thereby contributing directly to the projected decrease in funding costs. The remaining 50% of the capital will be directed towards expanding lending activities within the company's established segments. This injection of capital will support increased disbursement volumes, enabling Shriram Finance to capture a larger share of its target markets. The ability to lend more efficiently and at a lower cost of capital could translate into more competitive product offerings for customers, potentially boosting market share and revenue growth. This dual strategy of liability management and growth capital deployment underscores Shriram Finance's focus on both financial optimization and market expansion, leveraging the MUFG infusion to strengthen its economic position.